APA (7th ed.) Citation

Xia, Y., Miao, Y., Qian, S., Zhang, R., Qin, S., Xie, X., . . . Zhu, H. (2025). Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: A multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG). BMC Medicine, 23(1), 1. https://doi.org/10.1186/s12916-025-04418-y

Chicago Style (17th ed.) Citation

Xia, Yi, et al. "Zanubrutinib, Lenalidomide and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone as Initial Treatment in Non–germinal Center B-cell Diffuse Large B-cell Lymphoma: A Multi-center Phase 2 Study by Jiangsu Cooperative Lymphoma Group (JCLG)." BMC Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12916-025-04418-y.

MLA (9th ed.) Citation

Xia, Yi, et al. "Zanubrutinib, Lenalidomide and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone as Initial Treatment in Non–germinal Center B-cell Diffuse Large B-cell Lymphoma: A Multi-center Phase 2 Study by Jiangsu Cooperative Lymphoma Group (JCLG)." BMC Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12916-025-04418-y.